

# Parkinson-Alzheimer-Dementia Panel



## Blue Ridge Laboratories' Comprehensive Parkinson-Alzheimer-Dementia Panel

Blue Ridge Laboratories' Parkinson-Alzheimer-Dementia Panel examines 35 genes associated with an increased risk of developing neurodegenerative conditions: Parkinson's disease, Alzheimer's disease, and genetic disorders that cause dementia.

The Parkinson-Alzheimer-Dementia Panel was designed for Memory Care and Long Term Care facility residents and their medical providers. The genes on the panel have been carefully selected based on scientific literature, mutation databases and our experience.


### Who is testing for?

Testing is for patients with a personal and/or family history of Parkinson's disease, Alzheimer's disease, and dementia. If a pathogenic variant is identified in your patient, close relatives (children, siblings, and parents) are up to 50% more likely to also be at increased risk.



### Parkinson's and Alzheimer's disease facts and figures:

- Alzheimer's and Parkinson's are the number 1 and number 2 leading neurodegenerative conditions.
- Between 2000 – 2019, deaths from Alzheimer's disease increased 145%
- 1 in 3 seniors have Alzheimer's or other dementia
- 2% of those over 65 will be affected by Parkinson's Disease



### What are the potential benefits?

- Provides the patients and their families the opportunity to be better informed and take a proactive approach to their health
- Aids the planning and decision-making process for:
  - Treatment
  - Psychosocial counseling
  - Research study enrollment
  - Support programs for caregivers and patients.
- Patient's family members can also be tested to help define their risk.